Cargando…

FAME 2 – The best initial strategy for patients with stable coronary artery disease: Do we have an answer at last?

Detalles Bibliográficos
Autores principales:	ElGuindy, Ahmed M, Bonow, Robert O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bloomsbury Qatar Foundation Journals 2013
Materias:	Lessons from the Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963713/ https://www.ncbi.nlm.nih.gov/pubmed/24688985 http://dx.doi.org/10.5339/gcsp.2012.18

Ejemplares similares

FAME 2: Reshaping the approach to patients with stable coronary artery disease
por: ElGuindy, Ahmed M.
Publicado: (2015)

PARADIGM-HF: Have we achieved a new paradigm in the treatment of heart failure?
por: Bonow, Robert O., et al.
Publicado: (2014)

The RIME trial: Are we closer to the answer of when to repair ischemic mitral regurgitation?
por: Afifi, Ahmed, et al.
Publicado: (2013)

PCI versus CABG in patients with complex coronary artery disease: Time for reconciliation?
por: ElGuindy, Ahmed M, et al.
Publicado: (2013)

PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients
por: ElGuindy, Ahmed
Publicado: (2016)

HEAT-PPCI: A clear and welcome win for heparin
por: ElGuindy, Ahmed M.
Publicado: (2014)

ALDO-DHF & Paramount
por: ElGuindy, Ahmed M
Publicado: (2013)

TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?
por: ElGuindy, Ahmed M.
Publicado: (2013)

STREAM and FAST-MI – Pharmacoinvasive therapy: A continued role for fibrinolysis in the primary PCI era
por: ElGuindy, Ahmed M.
Publicado: (2014)

STREAM at one year: Further evidence supporting a pharmacoinvasive strategy in patients with STEMI
por: ElGuindy, Ahmed M.
Publicado: (2015)

PLATFORM at 90 days: Evaluating the clinical utility of FFRCT
por: Kharabish, Ahmed, et al.
Publicado: (2016)

STOP-HF: Expanding the role of HF programs into the community
por: ElMaghawry, Mohamed, et al.
Publicado: (2014)

BLOCK-HF: CRT gains new ground
por: ElGuindy, Ahmed M., et al.
Publicado: (2013)

Culprit lesion-only versus complete revascularization in patients with STEMI: Lessons learned from PRAMI, CvLPRIT, and DANAMI-3 PRIMULTI
por: Hassan, Ahmed, et al.
Publicado: (2015)

TASTE: One-year follow-up results
por: Elmahdy, Mahmoud Farouk, et al.
Publicado: (2015)

Overview of trials from AHA 2021
por: Gergis, Michael, et al.
Publicado: (2021)

CTS trials network: Rate control vs rhythm control for atrial fibrillation after cardiac surgery - Do bitter pills have blessed effects?
por: Afifi, Ahmed
Publicado: (2016)

APOC3: Triglycerides do matter
por: Hassan, Mohamed
Publicado: (2014)

Off-pump coronary artery bypass grafting (OPCABG): the beginning of the end?
por: Taggart, David
Publicado: (2013)

Dietary patterns and their association with acute coronary heart disease: Lessons from the REGARDS Study
por: Al Suwaidi, Jassim
Publicado: (2015)

Biocorrodible metals for coronary revascularization: Lessons from PROGRESS-AMS, BIOSOLVE-I, and BIOSOLVE-II
por: Bouchi, Yasir H., et al.
Publicado: (2015)

Is there a role for genetic risk assessment in the treatment of dyslipidemia in primary and secondary prevention of coronary heart disease?
por: Suwaidi, Jassim Al
Publicado: (2015)

Legacy effect of statins: 20-year follow up of the West of Scotland Coronary Prevention Study (WOSCOPS)
por: Kashef, Mohammed Amin, et al.
Publicado: (2016)

Bioresorbable polymeric scaffolds for coronary revascularization: Lessons learnt from ABSORB III, ABSORB China, and ABSORB Japan
por: Gogas, Bill D., et al.
Publicado: (2015)

TASTE: To aspirate, or not to aspirate, remains a question
por: Elmahdy, Mahmoud Farouk
Publicado: (2014)

STAMPEDE: Bariatric surgery gains more evidence based support
por: Al Suwaidi, Jassim
Publicado: (2014)

TAVI: New trials and registries offer further welcome evidence – U.S. CoreValve, CHOICE, and GARY
por: Pighi, Michele, et al.
Publicado: (2014)

RE-ALIGN: First trial of novel oral anticoagulant in patients with mechanical heart valves – The search continues
por: Shazly, Ahmed, et al.
Publicado: (2014)

SYMPLICITY HTN 3: The death knell for renal denervation in hypertension?
por: Patel, Hitesh C, et al.
Publicado: (2014)

CADUCEUS, SCIPIO, ALCADIA: Cell therapy trials using cardiac-derived cells for patients with post myocardial infarction LV dysfunction, still evolving
por: Yacoub, Magdi H, et al.
Publicado: (2013)

TRIOLOGY ACS: No benefit/No harm
por: Elmahdy, Mahmoud Farouk, et al.
Publicado: (2013)

ARCTIC: Additional proof against antiplatelet adjusted therapy
por: Elmahdy, Mahmoud Farouk, et al.
Publicado: (2013)

Clinical trials of bone marrow derived cells for ischemic heart failure. Time to move on? TIME, SWISS-AMI, CELLWAVE, POSEIDON and C-CURE
por: Raynaud, Christophe M., et al.
Publicado: (2013)

ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation
por: Kaba, Riyaz A, et al.
Publicado: (2013)

Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism
por: Said, Karim
Publicado: (2013)

Transfusion Indication Threshold Reduction (TITRe2) trial: When to transfuse and what to give?
por: Afifi, Ahmed, et al.
Publicado: (2015)

Gulf CARE: Heart failure in the Middle East
por: Hassan, Mohamed
Publicado: (2015)

CTS Trials Network: Surgical ablation of atrial fibrillation during mitral valve surgery - many questions unanswered
por: Afifi, Ahmed
Publicado: (2015)

The Copenhagen City Heart Study (Østerbroundersøgelsen)
por: Aguib, Yasmine, et al.
Publicado: (2015)

Macitentan in pulmonary arterial hypertension: The SERAPHIN trial
por: Said, Karim
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gntqcq20ujm6vogdns4ok7igmn